<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyEventTranscriptSummaryOutput xmlns:ns2="local" id="10791181"><Name>Q1 2018 Johnson &amp; Johnson Earnings Call</Name><Company>Johnson &amp; Johnson</Company><Drugs><Drug>epoetin alfa (Procrit/Eprex), Johnson &amp; Johnson</Drug><Drug>infliximab</Drug><Drug>ustekinumab</Drug><Drug>risperidone (depot injection, Medisorb), J&amp;J</Drug><Drug>rivaroxaban</Drug><Drug>lenalidomide</Drug><Drug>abiraterone</Drug><Drug>darunavir</Drug><Drug>ibrutinib</Drug><Drug>daratumumab</Drug><Drug>macitentan</Drug><Drug>selexipag</Drug><Drug>apalutamide</Drug><Drug>guselkumab</Drug><Drug>methylphenidate hydrochloride (oral controlled-release, OROS), ALZA</Drug></Drugs></ns2:com.thomsonreuters.ls.service.contract.soap.ontology.v1.OntologyEventTranscriptSummaryOutput>